Regeneron Pharma (REGN) PT Raised to $725 at BMO Capital

BMO Capital analyst Evan David Seigerman raised the price target on Regeneron Pharma (NASDAQ: REGN) to $725.00 (from $640.00) while maintaining an Outperform rating.

The analyst commented: "Much needed relief: Dupixent strength coupled with Eylea HD PFS and label expansion on the horizon. Given recent CRLs from manufacturing issues, we were highly encouraged with commentary around Eylea HD PFS filing/approval from a new facility in 2026, with RVO/Q4W dosing next month. We could finally be nearing an end of the manufacturing issues that have plagued the Eylea HD franchise since 2023. Continued Dupxient outperformance increases our confidence in the product's longterm growth potential as COPD sales continue to inflect higher; Target to $725."

You May Also Be Interested In

• Raymond James Starts SpyGlass Pharma (SGP) at Outperform
• Beyond Meat Inc. (BYND) PT Raised to $15 at TD Cowen citing reverse stock split
• Leerink Starts Freenome Inc. (FRNM) at Outperform